T. Rowe Price Associates’s Clover Health Investments CLOV Stock Holding History

T. Rowe Price Associates’s Portfolio CLOV Stock Details CLOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$710K	Buy	402,901 +67,377	+20%	+$146K	﹤0.01%	2302
2025 Q4	$789K	Sell	335,524 -33,305	-9%	-$91K	﹤0.01%	2181
2025 Q3	$1.13M	Buy	368,829 +18,570	+5%	+$53K	﹤0.01%	2002
2025 Q2	$978K	Buy	350,259 +197,759	+130%	+$650K	﹤0.01%	1998
2025 Q1	$548K	Buy	+152,500	New	+$612K	﹤0.01%	2217
2023 Q2	–	Sell	-69,854	Closed	-$60K	–	2901
2023 Q1	$60K	Sell	69,854 -153,349	-69%	-$168K	﹤0.01%	2768
2022 Q4	$207K	Buy	223,203 +5,269	+2%	+$7.03K	﹤0.01%	2517
2022 Q3	$371K	Buy	217,934 +81,834	+60%	+$214K	﹤0.01%	2276
2022 Q2	$291K	Buy	136,100 +57,605	+73%	+$153K	﹤0.01%	2452
2022 Q1	$279K	Buy	78,495 +32,178	+69%	+$93.3K	﹤0.01%	2578
2021 Q4	$172K	Buy	46,317 +21,745	+88%	+$133K	﹤0.01%	2790
2021 Q3	$182K	Buy	+24,572	New	+$210K	﹤0.01%	2747

Other funds holding CLOV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates's CLOV Position: Q1 2026 in Review

T. Rowe Price Associates increased its Clover Health Investments (CLOV) stake by 20% in Q1 2026, buying an estimated $146K and bringing the position to 402,901 shares worth $710K. The position accounts for ﹤0.01% of the portfolio, ranked #2302.

T. Rowe Price Associates first reported a position in CLOV in Q3 2021 and has held it in 12 quarters since. The position peaked at $1.13M in Q3 2025. 208 funds tracked by Wall St. Rank hold CLOV as of Q1 2026.

T. Rowe Price Associates held 402,901 shares of Clover Health Investments worth $710K as of Q1 2026.
T. Rowe Price Associates bought 67,377 Clover Health Investments shares in Q1 2026, an estimated $146K.
Clover Health Investments made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2302 holding.
T. Rowe Price Associates first reported a position in Clover Health Investments in Q3 2021 and has held it in 12 quarters since.
T. Rowe Price Associates's Clover Health Investments position peaked at $1.13M in Q3 2025.
208 funds tracked by Wall St. Rank held Clover Health Investments as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.